Literature DB >> 24658687

Metabolic control of YAP and TAZ by the mevalonate pathway.

Giovanni Sorrentino1, Naomi Ruggeri1, Valeria Specchia2, Michelangelo Cordenonsi3, Miguel Mano4, Sirio Dupont3, Andrea Manfrin3, Eleonora Ingallina1, Roberta Sommaggio5, Silvano Piazza6, Antonio Rosato5, Stefano Piccolo3, Giannino Del Sal1.   

Abstract

The YAP and TAZ mediators of the Hippo pathway (hereafter called YAP/TAZ) promote tissue proliferation and organ growth. However, how their biological properties intersect with cellular metabolism remains unexplained. Here, we show that YAP/TAZ activity is controlled by the SREBP/mevalonate pathway. Inhibition of the rate-limiting enzyme of this pathway (HMG-CoA reductase) by statins opposes YAP/TAZ nuclear localization and transcriptional responses. Mechanistically, the geranylgeranyl pyrophosphate produced by the mevalonate cascade is required for activation of Rho GTPases that, in turn, activate YAP/TAZ by inhibiting their phosphorylation and promoting their nuclear accumulation. The mevalonate-YAP/TAZ axis is required for proliferation and self-renewal of breast cancer cells. In Drosophila melanogaster, inhibition of mevalonate biosynthesis and geranylgeranylation blunts the eye overgrowth induced by Yorkie, the YAP/TAZ orthologue. In tumour cells, YAP/TAZ activation is promoted by increased levels of mevalonic acid produced by SREBP transcriptional activity, which is induced by its oncogenic cofactor mutant p53. These findings reveal an additional layer of YAP/TAZ regulation by metabolic cues.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24658687     DOI: 10.1038/ncb2936

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  319 in total

Review 1.  Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention.

Authors:  Lisa M Butler; Ylenia Perone; Jonas Dehairs; Leslie E Lupien; Vincent de Laat; Ali Talebi; Massimo Loda; William B Kinlaw; Johannes V Swinnen
Journal:  Adv Drug Deliv Rev       Date:  2020-07-23       Impact factor: 15.470

2.  RHOA activity in expanding blastocysts is essential to regulate HIPPO-YAP signaling and to maintain the trophectoderm-specific gene expression program in a ROCK/actin filament-independent manner.

Authors:  Yusuke Marikawa; Vernadeth B Alarcon
Journal:  Mol Hum Reprod       Date:  2019-02-01       Impact factor: 4.025

3.  Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer.

Authors:  Vidyalakshmi Sethunath; Huizhong Hu; Carmine De Angelis; Jamunarani Veeraraghavan; Lanfang Qin; Nicholas Wang; Lukas M Simon; Tao Wang; Xiaoyong Fu; Agostina Nardone; Resel Pereira; Sarmistha Nanda; Obi L Griffith; Anna Tsimelzon; Chad Shaw; Gary C Chamness; Jorge S Reis-Filho; Britta Weigelt; Laura M Heiser; Susan G Hilsenbeck; Shixia Huang; Mothaffar F Rimawi; Joe W Gray; C Kent Osborne; Rachel Schiff
Journal:  Mol Cancer Res       Date:  2019-08-16       Impact factor: 5.852

4.  Molecular Pathways: Hippo Signaling, a Critical Tumor Suppressor.

Authors:  Ana Sebio; Heinz-Josef Lenz
Journal:  Clin Cancer Res       Date:  2015-09-17       Impact factor: 12.531

5.  Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration.

Authors:  Jonathan W Haskins; Don X Nguyen; David F Stern
Journal:  Sci Signal       Date:  2014-12-09       Impact factor: 8.192

6.  Cholesterol Esterification Inhibition Suppresses Prostate Cancer Metastasis by Impairing the Wnt/β-catenin Pathway.

Authors:  Hyeon Jeong Lee; Jie Li; Renee E Vickman; Junjie Li; Rui Liu; Abigail C Durkes; Bennett D Elzey; Shuhua Yue; Xiaoqi Liu; Timothy L Ratliff; Ji-Xin Cheng
Journal:  Mol Cancer Res       Date:  2018-03-15       Impact factor: 5.852

7.  The effect of statins on survival in patients with stage IV lung cancer.

Authors:  Jenny J Lin; Nicole Ezer; Keith Sigel; Grace Mhango; Juan P Wisnivesky
Journal:  Lung Cancer       Date:  2016-07-06       Impact factor: 5.705

Review 8.  The interplay between cell signalling and the mevalonate pathway in cancer.

Authors:  Peter J Mullen; Rosemary Yu; Joseph Longo; Michael C Archer; Linda Z Penn
Journal:  Nat Rev Cancer       Date:  2016-08-26       Impact factor: 60.716

9.  Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment-resistant melanoma, colorectal, and lung cancer.

Authors:  Nicholas Theodosakis; Casey G Langdon; Goran Micevic; Irina Krykbaeva; Robert E Means; David F Stern; Marcus W Bosenberg
Journal:  Pigment Cell Melanoma Res       Date:  2018-10-22       Impact factor: 4.693

Review 10.  The Role of Cholesterol in Cancer.

Authors:  Omer F Kuzu; Mohammad A Noory; Gavin P Robertson
Journal:  Cancer Res       Date:  2016-04-05       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.